These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36430692)

  • 21. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
    Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
    CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
    Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
    Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
    Litwin T; Smoliński Ł; Członkowka A
    Neurol Neurochir Pol; 2018; 52(1):98-101. PubMed ID: 29110882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
    Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.
    Hundehege P; Cerina M; Eichler S; Thomas C; Herrmann AM; Göbel K; Müntefering T; Fernandez-Orth J; Bock S; Narayanan V; Budde T; Speckmann EJ; Wiendl H; Schubart A; Ruck T; Meuth SG
    Neural Regen Res; 2019 Nov; 14(11):1950-1960. PubMed ID: 31290453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

  • 29. Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn.
    Doolen S; Iannitti T; Donahue RR; Shaw BC; Grachen CM; Taylor BK
    Pain; 2018 Feb; 159(2):224-238. PubMed ID: 29140922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    Kasheke GDS; Holman SP; Robertson GS
    J Neuroimmunol; 2022 Sep; 370():577926. PubMed ID: 35863299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up.
    Ludwig R; Malla B; Höhrhan M; Infante-Duarte C; Anderhalten L
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory effects of siponimod on astrocytes.
    Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
    Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.
    Bail K; Notz Q; Rovituso DM; Schampel A; Wunsch M; Koeniger T; Schropp V; Bharti R; Scholz CJ; Foerstner KU; Kleinschnitz C; Kuerten S
    J Neuroinflammation; 2017 Jul; 14(1):148. PubMed ID: 28738885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series.
    Bianco A; Guerra T; Caputo F; Paolicelli D; Iaffaldano P
    Clin Neurol Neurosurg; 2024 Oct; 245():108475. PubMed ID: 39159567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.
    Wu Q; Mills EA; Wang Q; Dowling CA; Fisher C; Kirch B; Lundy SK; Fox DA; Mao-Draayer Y;
    JCI Insight; 2020 Feb; 5(3):. PubMed ID: 31935197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
    Zhang J; Zhang ZG; Li Y; Ding X; Shang X; Lu M; Elias SB; Chopp M
    Neurobiol Dis; 2015 Apr; 76():57-66. PubMed ID: 25680941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    Hussain R; O'Leary S; Pacheco FM; Zacharias TE; Litvak P; Sguigna P; Marder E; Kia K; Kooner K; Stüve O
    J Neurol; 2016 Mar; 263(3):606-10. PubMed ID: 26914924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Siponimod for the treatment of secondary progressive multiple sclerosis.
    Dumitrescu L; Constantinescu CS; Tanasescu R
    Expert Opin Pharmacother; 2019 Feb; 20(2):143-150. PubMed ID: 30517042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.